International Journal of Medical Sciences

Impact factor
2.399

24 September 2017

ISSN 1449-1907 News feeds of published articles

My Manuscript | My Account

Journal of Genomics now in PubMed/PubMed Central. Submit manuscript...

Journal of Biomedicinenew

Theranostics

Journal of Cancer

Oncomedicine

International Journal of Biological Sciences

Journal of Genomics

Journal of Bone and Joint Infection (JBJI)

Nanotheranostics

PubMed Central Indexed in Journal Impact Factor

Int J Med Sci 2017; 14(11):1088-1093. doi:10.7150/ijms.20171

Research Paper

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy

Shingo Nakamoto1,2✉, Fumio Imazeki1, Tatsuo Kanda1, Shuang Wu1, Masato Nakamura, Shin Yasui1, Akinobu Tawada1, Rintaro Mikata1, Tetsuhiro Chiba1, Makoto Arai1, Osamu Yokosuka1, Hiroshi Shirasawa2

1. Department of Gastroenterology, Graduate School of Medicine, Chiba University, Japan.
2. Department of Molecular Virology, Graduate School of Medicine, Chiba University, Japan.

Abstract

Background: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis.

Aims: We examined whether this genetic variation is associated with host lipids and treatment response.

Methods: A total of 101 Japanese patients who had underwent liver biopsy before treatment with pegIFN and ribavirin for HCV genotype 1b infection were retrospectively analyzed for association between IFNL3 genotypes (rs8099917) and clinical factors including histopathological features of the liver. The presence of >5% steatosis in the liver specimen was defined as hepatic steatosis.

Results: Forty patients (40%) had liver steatosis before therapy. Patients with IFNL3 minor genotype (non-TT) showed lower low-density lipoprotein cholesterol level (p=0.0045), higher γ-glutamyl transpeptidase level (p=0.0003) and higher prevalence of hepatic steatosis (p=0.0002). Advanced fibrosis [odds ratio (OR) 4.63, p=0.03] and IFNL3 major genotype (OR 0.13, p=0.001) were 2 independent factors for determining the presence of hepatic steatosis. Among the factors associated with sustained virological response, IFNL3 genotype was the most significant predictor, as per multivariate analysis.

Conclusions: Our results confirmed that IFNL3 genotype is associated with hepatic steatosis as well as IFN response.

Keywords: Hepatitis C virus, Interferon lambda 3, Peginterferon, Ribavirin, Hepatic steatosis

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Nakamoto S, Imazeki F, Kanda T, Wu S, Nakamura M, Yasui S, Tawada A, Mikata R, Chiba T, Arai M, Yokosuka O, Shirasawa H. Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy. Int J Med Sci 2017; 14(11):1088-1093. doi:10.7150/ijms.20171. Available from http://www.medsci.org/v14p1088.htm